Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

about

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

Item

http://www.wikidata.org/entity/Q58367209

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Immunogenicity of the CYD tetr ...... ed phase II study in US adults

@en

Immunogenicity of the CYD tetr ...... ed phase II study in US adults

@nl

type

Item

label

Immunogenicity of the CYD tetr ...... ed phase II study in US adults

@en

Immunogenicity of the CYD tetr ...... ed phase II study in US adults

@nl

prefLabel

Immunogenicity of the CYD tetr ...... ed phase II study in US adults

@en

Immunogenicity of the CYD tetr ...... ed phase II study in US adults

@nl

P1476

Immunogenicity of the CYD tetr ...... ed phase II study in US adults

@en

P2093

Anna Skipetrova

http://www.w3.org/2001/XMLSchema#string

Eric Plennevaux

http://www.w3.org/2001/XMLSchema#string

Judith Kirstein

http://www.w3.org/2001/XMLSchema#string

Manoj Thakur

http://www.w3.org/2001/XMLSchema#string

Mark Boaz

http://www.w3.org/2001/XMLSchema#string

Thomas Papa

http://www.w3.org/2001/XMLSchema#string

William Douglas

http://www.w3.org/2001/XMLSchema#string

P2860

The global distribution and burden of dengue

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial

Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact Performance

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.

Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.

Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction.

P2888

s12879-018-3389-x

P304

475

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12879-018-3389-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1107123503

http://www.w3.org/2001/XMLSchema#string

P698

30241510

http://www.w3.org/2001/XMLSchema#string

P921

Vaccination schedule

infectious disease

P932

6150954

http://www.w3.org/2001/XMLSchema#string